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Abstract 25 
Infection by Trypanosoma brucei gambiense is characterized by a wide array of clinical 26 
outcomes, ranging from asymptomatic to acute disease and even spontaneous cure. In this 27 
study, we investigated the association between macrophage migrating inhibitory factor (MIF), 28 
an important pro-inflammatory cytokine that plays a central role in both innate and acquired 29 
immunity, and disease outcome during T. b. gambiense infection. A comparative expression 30 
analysis of patients, individuals with latent infection and controls found that MIF had 31 
significantly higher expression in patients (n = 141; 1.25±0.07; p < 0.0001) and latent infections 32 
(n = 25; 1.23±0.13; p = 0.0005) relative to controls (n = 46; 0.94±0.11). Furthermore, expression 33 
decreased significantly after treatment (patients before treatment n = 33; 1.40±0.18 versus 34 
patients after treatment n = 33; 0.99±0.10, p = 0.0001). We conducted a genome wide eQTL 35 
analysis on 29 controls, 128 cases and 15 latently infected individuals for whom expression and 36 
genotype data were both available. Four loci, including one containing the chemokine CXCL13, 37 
were found to associate with MIF expression. Genes at these loci are candidate regulators of 38 
increased expression of MIF after infection. Our study is the first data demonstrating that MIF 39 
expression is elevated in T. b. gambiense-infected human hosts but does not appear to contribute 40 
to pathology. 41 
1. Introduction 42 
Found in sub-Saharan countries, human African trypanosomiasis (HAT), or sleeping 43 
sickness, is a neglected tropical disease. It is caused by Trypanosoma brucei gambiense in 44 
western and central Africa, and T. b. rhodesiense in eastern Africa. The two forms of the disease 45 
are considered lethal without treatment and both are transmitted by tsetse flies of the genus 46 
Glossina (order Diptera) (Buscher et al., 2017; Simarro et al., 2010). T. b. gambiense causes 47 
97% of all HAT cases and is classically described as a chronic disease with an early 48 
haemolymphatic phase (stage 1) characterized by non-specific signs. This is followed by a 49 
meningoencephalitic phase (stage 2) in which the parasites penetrate the blood brain barrier, 50 
leading to neurological disorders and more specific signs characterised by sleep disorder from 51 
which the name sleeping sickness is derived, consists of daytime somnolence and sudden 52 
overwhelming sleep urges, and nocturnal insomnia (Buscher et al., 2017; Checchi et al., 2008). 53 
However, findings show that T. b. gambiense infection can lead to a wide array of clinical 54 
outcomes, ranging from acute disease that progresses rapidly to the second stage  (Garcia et al., 55 
2000; Truc et al., 1997) to spontaneous self-cures (Checchi et al., 2008; Jamonneau et al., 2012) 56 
and even latent infections with very low blood parasitaemia that, in most cases, are not 57 
detectable by microscopy. Long-term follow up has shown that this latter type of latent infection 58 
may persist for several years (Jamonneau et al., 2012).  59 
The pathogenesis of T. b. gambiense HAT is poorly understood as disease development is 60 
dependent on the host immune response, the genetic variability of the parasites and the host-61 
parasite interactions (Garcia et al., 2006). To address this, a candidate gene study was recently 62 
performed in Guinea to explore the association between genes involved in host immunity and 63 
the disease. This study found significant associations in the APOL1 gene a component on the 64 
trypanosome lytic factor (TLF) that confers resistance to T. b. brucei infection and also with 65 
rs1818879 of interleukin-6 (IL6) (Kabore et al., 2017). Several suggestive associations were 66 
observed at the macrophage migration inhibitory factor (MIF) gene locus, although these did 67 
not remain significant after Bonferroni correction (Kabore et al., 2017). Although we did not 68 
observe significant genetic association at the MIF locus in our Guinean HAT cohort, MIF is 69 
nevertheless known as an important pro-inflammatory cytokine that plays a central role in the 70 
control of both innate and acquired immunity in a number of diseases (Calandra, 2003; Renner 71 
et al., 2005). Elevated serum levels of MIF have been found in patients with malaria (McDevitt 72 
et al., 2006), viral hepatitis (Kimura et al., 2006), HIV infection (Regis et al., 2010), rheumatoid 73 
arthritis (Morand et al., 2002), sepsis (Bozza et al., 2004), vasculopathy (Zernecke et al., 2008), 74 
and Chagas disease (Cutrullis et al., 2013). Importantly, it was also shown Stijlemans et al. 75 
showed that MIF mediates the pathogenic inflammatory immune response and increases the 76 
recruitment of inflammatory monocytes and neutrophils promoting the most prominent 77 
pathological features of experimental trypanosome infections (Stijlemans et al., 2014). 78 
Regarding Trypanosoma cruzi, MIF was also shown to play an important role in the host 79 
defence against acute infections, favouring the production of the pro-inflammatory cytokines 80 
during the early phase of infection (Reyes et al., 2006). These studies have prompted us to 81 
evaluate MIF expression in human T. b. gambiense infections. 82 
To establish a potential role for MIF in determining T. b. gambiense clinical diversity, we 83 
examined MIF transcript expression in a Guinean cohort. For this study, MIF mRNA expression 84 
levels were determined by qPCR in HAT patients before and after treatment, individuals 85 
harbouring long term latent infections and endemic uninfected controls. In addition, the 86 
availability of genome wide SNP data generated within the framework of the TrypanoGEN 87 
network for some of these individuals (Ilboudo et al., 2017) made it possible to identify 88 
expression quantitative trait loci (eQTLs) potentially involved in the regulation of MIF 89 
expression. The identification of these loci contributes to our understanding of how MIF 90 
expression is controlled and may have relevance to a wide range of infectious and immune-91 
pathophysiological disease.  92 
2. Materials and methods 93 
2.1.  Ethics statement 94 
Samples were collected during medical surveys conducted by the national control program 95 
(NCP) of the Republic of Guinea according to the national HAT diagnostic procedures 96 
approved by the Ministry of Health in Guinea. All participants were informed of the objective 97 
of the study in their own language and signed an informed consent form. For participants less 98 
than 18 years of age, informed consent was obtained from their parents. Approval for this study 99 
was obtained from the « comité consultative de déontologie et d’éthique » (CCDE) of the 100 
« Institut de Recherche pour le Développement » (1-22/04/2013). This study is part of the 101 
TrypanoGEN project that aims to understand the genetic basis of human susceptibility to 102 
trypanosomiasis. Samples were archived in the TrypanoGen Biobank at CIRDES (Ilboudo et 103 
al., 2017). 104 
2.2.  Study population 105 
All individuals participating in this study were identified during medical surveys performed 106 
between 2007 and 2011 by the NCP of the Republic of Guinea. Identification and sampling of 107 
study participants were performed in three active HAT foci (Forecariah, Dubreka and Boffa) 108 
located along the Guinean coast according to standard procedures describe previously (Ilboudo 109 
et al., 2011). For each participant, 5 ml of blood was taken in anticoagulant blood collection 110 
tubes to collect plasma samples and buffy coats for further DNA extraction. Two additional ml 111 
of blood were also taken with PAXgene Blood RNA tubes (PreAnalytiX). All samples were 112 
frozen in a portable freezer at -20°C in the field and were stored in the lab at -80°C. For all 113 
participants, the Card Agglutination Test for Trypanosomiasis (CATT) was performed. Direct 114 
microscopic examination of the buffy coat and/or the lymph node aspirate (if swollen lymph 115 
nodes were present) were performed if an individual was CATT positive, (Camara et al., 2010; 116 
Magnus et al., 1978). The immune trypanolysis test was performed at CIRDES on all plasma 117 
samples, as previously described (Jamonneau et al., 2010). For this study, 212 individuals were 118 
selected and three categories of phenotype were defined according to the following criteria: 119 
i. Cases or HAT patients (n=141): Parasitologically confirmed patients, with CATT 120 
plasma dilution end titers ≥ 1/4 and trypanolysis test (TL) positive. All HAT patients diagnosed 121 
within this study were treated according to the NCP procedures. Patients with HAT stage 1 122 
disease (CSF white cell counts, 5) were treated by daily injection of pentamidine for 8 123 
consecutive days. Early stage 2 patients (CSF white cell counts 6-20) were treated with one 124 
injection of pentamidine every 2 days for 20 days (10 total injections). Late stage 2 patients 125 
(CSF white cell count, > 20) were treated with three cycles of melarsoprol injections (one-third 126 
of the dose on the 1st day, two-thirds of the dose on the 2nd day and a full dose on days 3 and 4) 127 
administered 10 days apart. Of the 141 patients, 33 were sampled again 6 months after treatment 128 
at their first follow-up and were included in this study to examine MIF expression before and 129 
after treatment. 130 
ii. Latent infections or Seropositive (n=25): individuals with CATT plasma dilution end 131 
titers ≥ 1/4, TL positive, parasitology negative (no trypanosomes detected by mAECT and/or 132 
by examination of cervical lymph node aspirate when cervical adenopathies were present) and 133 
who maintained this phenotype for least two years. 134 
iii. Endemic controls (n=46): Individuals with negative CATT results and negative TL, 135 
living in the same villages as a HAT patient and/or a seropositive subject. 136 
The age and gender characteristics of the different study groups is given in supplementary Table 137 
S1. 138 
2.3.  mRNA preparation and cDNA synthesis 139 
Total mRNA from blood was extracted with the PAXgene Blood RNA kit (PreAnalytiX) and 140 
quantified with a NanoDrop spectrophotometer (NanoDrop Technologies). The mRNA quality 141 
was checked using the RNA Integrity Number (RIN) on an Agilent 2100 Bioanalyzer with the 142 
RNA 600 Nano LabChip (Agilent Technologies). Total mRNA was reverse transcribed 143 
according to the manufacturer’s instructions, using High Capacity cDNA Reverse Transcription 144 
kit, Applied Biosystems and RNase inhibitor (Applied Biosystems) at a final concentration of 145 
1.0 U/ml. The cDNAs were stored at -20°C and diluted to 1:5 with RNase-free water for use as 146 
a template in the real-time PCR analysis. 147 
2.4.  MIF expression assays by RT-qPCR 148 
The real-time quantitative PCR analysis was conducted using the AriaMx machine (Agilent 149 
Technologies). All of the TaqMan RT-qPCR reagents, including the primers and probes, were 150 
purchased from Applied Biosystems. The RT-qPCR analysis was conducted using predesigned 151 
and optimized Assays on Demand (Applied Biosystems). The following assays were used: MIF 152 
(ID: Hs00236988_g1) and TBP (ID: Hs00427621_m1). The reaction parameters were a 2min 153 
at 50°C hold and a 5min at 95°C hold, followed by 45 cycles of 15s at 95°C for a melting, and 154 
1min at 60°C for annealing and extension. All of the measurements were performed in triplicate. 155 
A relative quantitation was conducted using TBP as a reference gene (Ledderose et al., 2011).  156 
The parameter cycle threshold (Ct) was defined as the cycle number at which the fluorescence 157 
intensity exceeds a fixed threshold. Relative amounts of mRNA for target genes were calculated 158 
using the comparative Ct method (2-∆∆Ct). As the assays were optimized for PCR efficiency by 159 
the manufacturer, the mRNA-expression levels were estimated according to the delta-Ct values. 160 
2.5.  Genotype data 161 
DNA was extracted from buffy coat (BC) samples using a Qiagen DNA extraction kit 162 
(QIAamp DNA Blood Midi Kit) following the manufacturer’s instructions. DNA extracts were 163 
stored at -20˚C. All DNA samples were quantified on a NanoDrop spectro-photometer, and 164 
shipped to Illumina, San Diego, California where they were genotyped on the H3Africa 2.5 165 
million SNP chip. Genotypes were extracted from the Illumina genotype file and converted to 166 
Plink format using the H3ABioNet Nextflow topbottom.nf workflow in the H3ABioNet GWAS 167 
pipeline (https://github.com/h3abionet/h3agwas). 168 
2.6.  Statistical analysis 169 
2.6.1. Differential Gene Expression analysis.  170 
The 2-∆∆CT method was applied to determine gene expression levels for each individual (Livak 171 
and Schmittgen, 2001) and results used to compare the relative expression of MIF between 172 
HAT phenotypes. The Shapiro-Wilk test was initially used to test the null hypothesis (H0) that 173 
the level of expression followed a normal distribution (p-value > 0.05). As MIF expression 174 
levels did not follow a normal distribution, we used the non-parametric Wilcoxon-test to 175 
perform the intergroup comparisons. This tested the H0 that there was no difference in the mean 176 
expression of MIF between the phenotypes. We also used a paired Wilcoxon-test to compare 177 
MIF expression level in the same patient before and after treatment. Association of MIF 178 
expression with recorded covariates (gender, age, disease focus and HAT phenotypes) were 179 
analysed in univariate or multivariate linear regression. All of the data are presented as means 180 
± CI95 and pairs of conditions and p-values < 0.05 were considered significant. All analyses 181 
were performed with R 3.4.4 software (R Development Core Team, 2018). 182 
2.6.2. Expression QTL analysis.  183 
A genome wide association study was undertaken in Plink to identify SNP associated with MIF 184 
expression levels. Quality control of the genotyped data was performed using Plink 1.9. Closely 185 
related samples were identified and one of each pair of close relatives were removed. We 186 
removed duplicate samples and samples with missing data > 5% and loci with minor allele 187 
frequencies < 5% and loci which were not in Hardy-Weinberg equilibrium (p < 0.001). We 188 
created a Plink phenotype file (Sample ID, sex, age, expression of MIF) containing 172 samples 189 
constituted of 29 controls, 128 cases and 15 individuals with latent infections for whom both 190 
expression and genotype data were available. We used linear regression in Plink 1.9 to perform 191 
eQTL analysis using the “linear” function, including the disease status as a covariate.  Loci 192 
where significant eQTL were detected were reanalysed using a much denser set of SNP markers 193 
obtained by imputation from our genotype data and 1000 genomes reference data. Imputation 194 
was done by H3ABioNet at the University of Capetown using 1000 genome project genotypes 195 
as reference (Genomes Project et al., 2015). 196 
3. Results 197 
3.1.  MIF expression in HAT patients, individuals with latent infections and endemic 198 
controls 199 
MIF mRNA quantification was conducted on 212 samples that consisted of healthy 200 
endemic controls n = 46 (21.70%) and T. b. gambiense-infected individuals that were 201 
subdivided into two phenotypes: 1) patients with active HAT n = 141 (66.51%) of whom 33 202 
(23.40%) were sampled again after treatment, and 2) individuals with latent infections n = 25 203 
(11.79%) who tested positive in serology, but were negative upon microscopic examination and 204 
exhibited few or no symptoms. These individuals were followed for a period of at least two 205 
years and none developed detectable blood parasitaemia during their follow up despite 206 
remaining positive in serology. The sex ratio (male: female) of the study population was 1.41 207 
(124/88) and the mean age (range) was 32.76 (5–85) years. Detailed characteristics of the study 208 
cohort are provided in Table S1. 209 
MIF expression levels were assayed by RT-qPCR and compared between groups of 210 
individuals. As shown in Fig 1 and Table S2, MIF expression levels were found to be 211 
significantly elevated in patients (1.25±0.07; p < 0.0001) and individuals with a latent infection 212 
(1.23±0.13; p = 0.0005) when compared to controls (0.94±0.11). In order to analyse further 213 
relation between MIF expression levels and infection by T. b. gambiense, we tested the effect 214 
of the recorded covariates (gender, age, disease focus and HAT phenotypes) and MIF 215 
expression levels in a linear regression analysis (Table 1). No significant association of MIF 216 
expression with gender, age and disease focus was found in the univariate model (p > 0.05). In 217 
the multivariate model MIF expression was significantly associate to the infection status (p < 218 
0.0001). No expression differences (p = 0.809) were observed between HAT cases (1.25±0.07) 219 
and individuals with latent infections (1.23±0.13) (Fig 1). These results suggest that MIF 220 
expression is induced during T. b. gambiense infection in humans but expression levels are not 221 
correlated with the clinical status. The MIF mean expression level decreased significantly in 222 
patients after treatment (1.40±0.18 before treatment versus 0.99±0.10 after treatment; p = 223 
0.0001) and was similar to expression levels observed in controls (0.94±0.11; p = 0.255).  224 
3.2.  Localisation of MIF expression quantitative trait loci 225 
We next performed an eQTL analysis using our MIF expression data and genotype data 226 
available for a subset of samples to identify SNP loci that were associated with MIF expression. 227 
In all e-QTLs analysis of MIF expression, the infection status was included as a covariate in the 228 
regression analysis. Samples were genotyped on the H3Africa Illumina SNP chip that contains 229 
2.5 million SNP loci and is enriched for common African SNPs. We found SNPs at four loci, 230 
located on chromosomes 1, 3, 4 and 10 respectively, that had significant associations with MIF 231 
expression (p < 10-7) (Fig 2, Table 2). We did not observe any association signal on 232 
chromosome 22 at the MIF locus. SNPs were annotated with the closest gene(s) using Genome 233 
Reference Consortium Human Build 37 (GRCh37/hg19) data (Table 3). In particular, a locus 234 
containing chemokine (C-X-C motif) ligand 13 (CXCL13) was found to be significantly 235 
associated with MIF expression (p=7.12x10-8). This chemokine is involved in many 236 
inflammatory responses, primarily involved in B cells. There was not information about the 237 
genes at the other eQTL loci to predict the mechanism of their effect on MIF expression (Table 238 
2). Genetic association at these identified loci were then further explored by the mean of 239 
imputation to increase the number of SNPs in these chromosomal regions (Fig 2b, 2c, 2d, 2e). 240 
At each candidate loci, additional SNPs were found to be significantly associated with MIF 241 
expression levels thus supporting the genome wide association results (Table S3). A sharp peak 242 
of association was observed for the eQTL on chromosome 3 whereas association signals were 243 
broader for the eQTLs on chromosome 1, 4 and 10. 244 
In order to assess the importance of T. b. gambiense infected individuals in the 245 
identification of MIF eQTLs, we repeated the analysis for the four identified regions on 246 
chromosomes 1, 3, 4 and 10 on several groups of individuals: all, HAT cases and controls and 247 
infected individuals only (HAT cases and latent infections). In all cases lower mean p-values 248 
were obtained in the analysis excluding controls (Fig 3) although effectives were lower in this 249 
analysis. Most controls had low MIF expression levels and were thus probably not much 250 
informative in the analysis. This was particularly true for the e-QTLs on chromosomes 3 and 251 
10 for which the strength of genetic association appears highly dependent of T. b. gambiense 252 
infected individuals. 253 
4. Discussion 254 
 Although several studies have investigated the role of MIF polymorphisms rs36086171 255 
and rs12483859 in HAT resistance/susceptibility (Ahouty et al., 2017; Kabore et al., 2017; Ofon 256 
et al., 2017), the present study is the first to look at MIF expression levels in a HAT endemic 257 
population containing individuals with latent infections. The principal finding was that, as 258 
observed for other infectious diseases, MIF expression is elevated during T. b. gambiense 259 
infection. However, levels did not correlate with disease severity as expression was found to be 260 
elevated in both HAT patients with active disease and individuals harbouring latent infections. 261 
A second major finding was the identification of four eQTLs involved in the control of MIF 262 
expression that may be relevant in wide array of disease settings. This demonstrates that 263 
studying humans infected with pathogens that stimulate an immune response may provide new 264 
insights into wider immune regulation mechanisms. 265 
MIF is known to be a critical upstream mediator of innate immunity and is involved in a 266 
number of pathophysiological inflammatory processes such as glomerulonephritis (Yang et al., 267 
1998) and asthma (Mizue et al., 2005). It is a pleiotropic cytokine produced by a variety of 268 
immune cells, including lymphocytes, macrophages and pituitary cells (Calandra et al., 1995). 269 
MIF expression is regulated by several factors, such as exposure to endotoxins, inflammatory 270 
cytokines and glucocorticoids, and exhibits a wide range of immune activities. This can include 271 
the induction of the Toll-like receptor 4 (TLR4) gene and the induction of inflammatory 272 
cytokines, such as INFG, TNFA, IL8, IL6 or IL12. MIF is also known to sustain macrophage 273 
activation and the secretion of microbicidal molecules, including nitric oxide (Rosado and 274 
Rodriguez-Sosa, 2011). 275 
Up-regulation of MIF expression has been reported for many infectious and parasitic 276 
diseases, demonstrating that MIF can play either a protective or deleterious role in the immune 277 
response to different pathogens (Rosado and Rodriguez-Sosa, 2011). For example, the TLR4-278 
mediated response to T. cruzi has been reported as one of the main pathways involved in the 279 
early production of cytokines associated with human innate immunity during the acute stage 280 
(Oliveira et al., 2004). Other studies have shown that MIF secreted by activated macrophages 281 
plays an important role in innate immune defences against Mycobacterium tuberculosis by 282 
acting in an autocrine fashion to inhibit the growth of virulent mycobacteria (Oddo et al., 2005). 283 
Low expression alleles of MIF were also shown to confer an increased risk of M. tuberculosis 284 
disease in some populations (Das et al., 2013). In the present study, we found that MIF 285 
expression was significantly upregulated during T. b. gambiense infections in both patients with 286 
active disease and individuals harbouring latent infections. T. b gambiense thus seems to be a 287 
potent inducer of MIF in humans but MIF does not appear to control infection outcome, at least 288 
in the Guinean population. This is in contrast to a previous study in mice, where MIF expression 289 
was found to be increased in susceptible mice infected by T. brucei. In this model, MIF was 290 
proposed to be a major element promoting the most prominent pathological features of 291 
experimental trypanosomiasis (Stijlemans et al., 2014). Results presented here suggest that this 292 
may not be the case in our Guinean cohort. Interestingly other proinflammatory cytokines that 293 
are modulated by MIF, including IL8 and IL6, have been found to be significantly increased in 294 
individuals with latent infections (Gineau et al., 2016; Ilboudo et al., 2014). In contrast, 295 
susceptibility to disease was associated with increased levels of immunosuppressive molecules, 296 
such as IL-10 and soluble HLA-G (Gineau et al., 2016; Ilboudo et al., 2014). This suggest that 297 
the control of resistance/susceptibility to HAT occurs downstream of MIF activation in our 298 
study population. 299 
This study has also identified four trans-acting eQTLs that are associated with the 300 
control of MIF expression. No signs of association where found at the MIF locus on 301 
chromosome 22, despite multiple cis-eQTL SNP being reported by the larger study undertaken 302 
by GTEx Consortium (GTEx Consortium, 2015). This could be due to the lower coverage of 303 
the H3Africa Illumina SNP chip in this region. It is noteworthy however that only suggestive 304 
genetic associations were observed between MIF polymorphisms and HAT in this Guinean 305 
population (Kabore et al., 2017). Another explanation is that MIF expression regulatory 306 
polymorphisms are too rare in this population for associations to be detected with our sample 307 
size. Importantly,  most studies examining MIF regulation in infectious disease have focused 308 
on cis-regulatory elements (Rosado and Rodriguez-Sosa, 2011). Our study suggests that other 309 
loci in the genome may also play an important role and should be investigated further to better 310 
understand the mechanisms of MIF regulation and implication in disease exacerbation or 311 
infection control. The eQTL on chromosome 4 encompasses the CXCL13 gene. Excessive 312 
CXCL13 production has been associated with the development of systemic lupus 313 
erythematosus nephritis and recombinant CXCL13 has been shown to induce the up-regulation 314 
of MIF expression in human podocytes in vitro (Worthmann et al., 2014). Interestingly two 315 
genes coding for RNA regulatory molecules, a small nucleolar RNA (SNORD2) and a micro 316 
RNA (MIR3924), were identified on chromosome 10 in this study, neither of these appeared to 317 
have any homology with sequences at the MIF locus suggesting that any regulatory effect that 318 
they might have on MIF is indirect through other genes. However, we only considered genes 319 
that either encompassed the significant SNP or were the closest gene when the SNP was located 320 
in an intergenic region. As shown with our imputed data (Fig 2), association signals can extend 321 
up to a 100kb on chromosomes 3, 4 and 10 suggesting that other candidate genes involved in 322 
MIF regulation may be located further away from the index SNP. 323 
Furthermore, we found that the most significant eQTLs that may be involved in MIF 324 
expression regulation were obtained in analyses using infected individuals only (including HAT 325 
patients and individuals with latent infections) and excluding controls (Fig 3). This would 326 
suggest that MIF is actively regulated by trans-acting genes only when there is an inflammatory 327 
response, and that this trans-regulation dominates over any cis-regulation. At other times basal 328 
expression may be cis-regulated but our sample of 29 controls may have been too small to detect 329 
this or there may be no common regulatory variants at MIF in this population. This suggests 330 
that the T. b. gambiense infection has boosted the power to detect genetic loci controlling MIF 331 
expression. As potent inducers of immune responses, pathogens may thus serve as a valuable 332 
tool that may increase the power to unravel regulatory mechanisms involved in the control of 333 
critical mediators of immunity in human populations. 334 
5. Conclusion 335 
This study has shown that T. b. gambiense infection induces MIF expression in humans and has 336 
enabled us to locate four trans-acting eQTLs controlling MIF expression. As most pathogens 337 
are potent inducers of immunological molecules, such as MIF, our study demonstrates that 338 
combining clinical phenotypes, whole genome genotypes and expression data in infectious 339 
diseases, may contribute to improving our knowledge of immune regulation and susceptibility 340 
to other immune-pathophysiological diseases. 341 
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Figure legends 514 
Fig 1: MIF expression in HAT patients, individuals carrying latent infections and endemic 515 
controls. (A) MIF expression levels according to the clinical status: endemic controls (n = 46), 516 
HAT patients or cases (n = 141), latent infections (n = 25). (B) MIF expression levels in patient 517 
before treatment (n = 33) and the same patient after treatment (n = 33). ****p < 0.0001, **p < 518 
0.01, ns: not significant. 519 
Fig 2: Manhattan plots showing the locations of MIF expression eQTL. The e-QTL analysis 520 
was performed by linear regression using the clinical status (HAT patient, latent infection, 521 
endemic control) as a covariate. A. eQTL mapping using the whole genome genotype dataset 522 
from the Illumina 2.5M SNP chip.  Association results after including imputed SNPs at the 523 
candidate e-QTLs on chromosome 1 (B.), chromosome 3 (C.), chromosome 4 (D.) and 524 
chromosome 10 (E.). 525 
Fig 3: Bar plot representing the mean p-value of significant imputed SNPs at each eQTL 526 
locus according to the infection status. For each model the phenotype was used as covariate 527 
in the linear regression analysis. Covariate coding: 1-Infected versus Controls (n = 172): 528 
Controls were coded 1 and both active and latent infections were coded 2; 2- HAT cases versus 529 
Controls (n= 157): Controls and active cases were coded 1 and 2 and latent infections were 530 
coded 0 (missing) and were excluded; 3-HAT cases versus Latent (n= 143): Latent infections 531 
were coded 1, active cases were coded 2, controls were coded 0 and were excluded. 532 
  533 
Table 1: Analysis of MIF expression levels according to recorded covariates 534 
Covariates Univariate Multivariate 
 n MIFa p p 
Sex 
Females  
Males 
Age  
≤ 24 years 
25 – 39 years  
≥ 40 years 
Disease focus  
Forecariah  
Dubreka  
Boffa 
HAT phenotypes  
Controls  
Latent infections  
HAT 
 
88  
124  
 
68  
77 
67 
 
61 
106 
45 
 
46 
25 
141 
 
1.22 ± 0.10 
1.16 ± 0.07 
 
1.15 ± 0.10 
1.21 ± 0.11 
1.19 ± 0.09 
 
1.22 ± 0.13 
1.20 ± 0.71 
1.27 ± 0.13 
 
0.94 ± 0.11 
1.23 ± 0.13 
1.25 ± 0.07 
 
 
0.3121 
 
 
0.2866 
 
 
 
0.0951 
 
 
<0.0001 
 
 
 
0.2250 
 
 
0.2614 
 
 
 
0.0395* 
 
 
<0.0001*** 
 
a Mean fold change ± mean confidence interval 535 
Table 2: SNPs reaching genome wide significance in the MIF e-QTL analysis.  536 
CHR SNP BP A1 TEST NMISS BETA STAT P 
1 kgp15347739 116918691 G ADD 120 0.5036 5.937 3.04E-08 
3 snp-known116300863 115325154 A ADD 149 0.4603 5.642 8.44E-08 
4 kgp20876446 78506066 G ADD 120 0.5356 5.754 7.12E-08 
10 snp-known78014716 58884536 C ADD 120 0.5346 5.696 9.29E-08 
CHR: Chromosomes, SNP: single nucleotide polymorphism, A1: minor allele name, BP, base-pair physical 537 
position, ADD: additive model. The e-QTL analysis was performed on the whole data set (n=172) using a linear 538 
regression model with the clinical status as a covariate. 539 
Table 3: Proximal e-QTLs candidate genes controlling MIF expression.  540 
CHR SNP Gene name Gene stable ID Gene description 
1 kgp15347739 AL136376.1 ENSG00000269279.1 Uncharacterized protein  
3 snp-known116300863 RP11-190P13.1 ENSG00000244157.1 
eukaryotic translation initiation factor 4E 
family member 2 pseudogene 2 
3 snp-known116300863 GAP43 ENSG00000172020.8 growth associated protein 43  
4 kgp20876446 CXCL13 ENSG00000156234.7 chemokine (C-X-C motif) ligand 13  
10 snp-known78014716 SNORD2 ENSG00000238707.1 Small nucleolar RNA SNORD2  
10 snp-known78014716 MIR3924 ENSG00000264747.1 microRNA 3924  
CHR: Chromosomes, SNP: single nucleotide polymorphism. Each SNP reaching genome wide association 541 
significance was annotated with either the gene they were located in or the genes immediately upstream or 542 
downstream for intergenic SNPs. 543 
Supporting Information Legends 544 
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Table S3: SNPs reaching genome wide significance in the MIF e-QTL analysis with 547 
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